Applications of (1,2,3,4-Tetrahydro-Isoquinolin-1-Yl)-Acetic Acid in Industrial Manufacturing

As a direct manufacturer, we supply (1,2,3,4-Tetrahydro-Isoquinolin-1-Yl)-Acetic Acid for advanced use across select industrial sectors. Our technical grade production supports downstream applications where traceability, standard conformity, controlled formulation, and reproducible integration into formulations drive both regulatory and commercial success. Below are the established use scenarios where this intermediate delivers measurable value in commercial manufacturing environments.

1. Pharmaceutical Intermediate for Active Pharmaceutical Ingredients (APIs)

Pharmaceutical factories use this compound as a core intermediate in synthesizing certain tetrahydroisoquinoline-based APIs, including some antihypertensive and neuroactive drug molecules. In multi-step syntheses, the material is introduced in the intermediate stages, supporting precise ring modifications for target molecule construction. Production requires strict adherence to pharmaceutical standards and finely tuned loading, as even minor deviation in the input ratio impacts yield and impurity profiles.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• EU GMP EudraLex Volume 4 (API intermediate section)
• USP <795>/<797> and Ph. Eur. Monographs for relevant APIs
• Drug Master File (DMF) supporting documentation required by FDA

Typical usage ratio

• 0.2–0.35 molar equivalents relative to target API batch size; precise amount adjusted per synthetic step and target molecular architecture

Downstream process integration

• Charged in the step following nucleophilic substitution or amidation; introduced to the reactor in solvent medium at controlled temperature; reacts under nitrogen or argon atmosphere; downstream purification by extraction and crystallization prior to API coupling or ring closure

Final product types

• Bulk APIs based on tetrahydroisoquinoline scaffolds (e.g., cardiovascular agents, CNS drugs)
• Pharmaceutical intermediates supplied for finished dosage manufacturing

2. Building Block for Fine Chemical Synthesis (Chiral Catalysts and Ligands)

Chemical process developers in fine chemicals utilize this intermediate to access custom ligands for asymmetric hydrogenation and other enantioselective transformations. Its rigid tetrahydroisoquinoline core serves as a starting material for functionalization, and downstream users incorporate it to produce high-performance chiral catalysts used in both batch and continuous flow systems.

Industry compliance standards

• ISO 9001:2015 Quality Management Systems
• Scheme B assessment per REACH Annex VII for specialty synthesis chemicals
• Internal customer QC protocols for chiral purity and residual contamination
• Specific customer technical agreements for fine chemical intermediates

Typical usage ratio

• 5–15 weight% relative to the total catalytic ligand batch; adjustment depends on reaction scalability and performance in target transformation

Downstream process integration

• Introduced at early synthetic stages for ligand construction; functional group derivatization or N-acylation performed under inert atmosphere, followed by direct coupling to phosphines, amines, or other catalyst cores in sequence

Final product types

• Chiral ligands for metal-catalyzed reactions
• Custom catalysts supplied to research and process manufacturing customers

3. Intermediate for Agrochemical Synthesis (Herbicide and Plant Growth Regulator Precursors)

Producers of advanced agrochemicals use this material as a core building block in the assembly of novel heterocyclic herbicides and plant growth regulators. The raw material is essential to constructing intermediate scaffolds for subsequent functionalization and biological activity tuning, entering the multi-step synthesis routes of patented agrochemical active substances.

Industry compliance standards

• ISO 9001:2015 for chemical production
• FAO/WHO Specifications and Evaluations for Agricultural Pesticides
• REACH registration for substances supplied over 1 tonne/year to EU
• OECD GLP (Good Laboratory Practice) for substances destined for regulatory studies

Typical usage ratio

• Utilized at 0.15 to 0.3 molar equivalents per agrochemical synthetic batch, with adjustment per the intended heterocycle modification strategy

Downstream process integration

• Added in early backbone generation during N-alkylation or acylation stages; subsequent steps proceed with oxidation or coupling to side chains, prior to formulation into technical concentrate

Final product types

• Agrochemical active ingredient intermediates
• Technical concentrates for blending into herbicides or plant growth regulators

4. Research and Development Reagent in Medicinal Chemistry Innovation

Contract research organizations (CROs) and discovery laboratories procure this compound as a reagent for early-phase medicinal chemistry, especially in generating new tetrahydroisoquinoline derivatives with potential bioactivity. Its performance as a highly pure starting material is crucial to reproducibility and scalable transfer from bench to preclinical supply.

Industry compliance standards

• GLP (Good Laboratory Practice) for tox and pharmacology support batches
• ISO 9001:2015 (Certified for reagent and R&D intermediate supply)
• Material Test Reports and analytical COA for each batch (NMR, HPLC, MS data)
• Ethical procurement policies for R&D chemicals

Typical usage ratio

• Dependence on the research protocol; typically 0.005–0.04 molar equivalents per reaction in lead optimization or analog synthesis, scaled by desired compound library size

Downstream process integration

• Introduced directly in solution-phase or solid-phase synthetic protocols; utilized in combinatorial synthesis, scaffold diversification, and high-throughput route exploration; post-reaction, intermediates subjected to analytical purification

Final product types

• Compound libraries and screening molecules for drug discovery
• Pharmacological probe compounds